◆英語タイトル:Oragenics Inc (OGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10060
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Oragenics Inc (Oragenics) focuses on the development and commercialization of novel antibiotics against infectious disease that includes treatments for oral mucositis, healthcare associated infections, obesity and dental disorders. The company develops its product candidates based on various technologies such as Lantibiotics which is a class of antibiotics with a novel mechanism of action active against several multi-drug resistant organisms; live biotherapeutics, which utilizes genetically modified bacteria to treat oral indications and SMaRT Replacement Therapy which is based on the creation of genetically modified strain of bacteria colonizing in the oral cavity and replaces native bacteria that cause tooth decay. Oragenics is headquartered in Tampa, Florida, the US.
Oragenics Inc (OGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oragenics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Intrexon Enters into Co-Development Agreement with Oragenics 10
Licensing Agreements 11
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11
Equity Offering 13
Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13
Oragenics Prices Private Placement of Shares for USD1.8 Million 15
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16
Oragenics Raises USD6.7 Million in Private Placement of Shares 17
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19
Oragenics Raises USD4.7 Million in Private Placement of Shares 20
Oragenics Completes Public Offering Of Shares For US$11 Million 22
Oragenics Completes Private Placement Of Shares For US$4 Million 23
Oragenics Completes Private Placement Of Common Stock For US$13 Million 24
Asset Transactions 25
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25
Oragenics Inc – Key Competitors 26
Oragenics Inc – Key Employees 27
Oragenics Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Apr 18, 2017: Oragenics Provides First Quarter 2017 Update 29
Product News 30
06/06/2017: Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference 30
03/19/2018: Oragenics Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile 31
Clinical Trials 32
Mar 23, 2018: Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis 32
Aug 31, 2017: Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34
List of Tables
Oragenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oragenics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intrexon Enters into Co-Development Agreement with Oragenics 10
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11
Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13
Oragenics Prices Private Placement of Shares for USD1.8 Million 15
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16
Oragenics Raises USD6.7 Million in Private Placement of Shares 17
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19
Oragenics Raises USD4.7 Million in Private Placement of Shares 20
Oragenics Completes Public Offering Of Shares For US$11 Million 22
Oragenics Completes Private Placement Of Shares For US$4 Million 23
Oragenics Completes Private Placement Of Common Stock For US$13 Million 24
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25
Oragenics Inc, Key Competitors 26
Oragenics Inc, Key Employees 27
Oragenics Inc, Other Locations 28
List of Figures
Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8